Atacicept's Long-Term promise for kidney disease
NCT ID NCT06674577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug remains safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atacicept
- What this could lead to
- If successful, this could confirm atacicept as a safe long-term treatment to slow kidney damage in IgA nephropathy.
- What could go wrong
- This is an extension study, not a new treatment test. It may show side effects or limited benefit over time, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vera Therapeutics
Brisbane, California, 94005, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease
- New pill aims to tame kidney disease in Long-Term trial